Nama's AI scorecard currently rates Nuvation Bio Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NUVB report earnings?

Nuvation Bio's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$0.09.

What is the NUVB price target?

The median analyst price target from 11 analysts is $12.00, with a range of $7.00 – $21.00.

Is NUVB Shariah compliant?

Nama's AAOIFI-style screen reads Nuvation Bio as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Nuvation Bio (NUVB)

Healthcare · Biotechnology · NYSE

Nuvation Bio (NUVB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.47B and a free-cash-flow yield of -12.7%. Over the most recent reported fiscal year, revenue grew 699.0%. Nama's AI scorecard rates it Sell, 3.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.4/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -3.2% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-60.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.47B
Trailing P/E	—
Price / book	5.7
Price / sales	8.7
FCF yield	-12.7%
Dividend yield	—
Gross margin	88.2%
Operating margin	-81.0%
Net margin	-88.2%
Revenue growth (YoY)	+699.0%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.6
Exchange	NYSE
Sector	Healthcare
Industry	Biotechnology

NUVB earnings

Next report: Mar 2, 2027 (Q4 2026, EPS estimate -$0.09). Beat the EPS estimate in 1 of 3 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.09	-$0.10	+10.0%	$44.95M
Q2 2026	Aug 6, 2026	-$0.15	-$0.12	-25.0%	$31.69M
Q1 2026	May 4, 2026	$0.01	—	—	$83.23M
Q4 2025	Mar 2, 2026	-$0.09	-$0.04	-125.0%	$41.87M

NUVB analyst price target

Median target $12.00 from 11 analysts, ranging $7.00 – $21.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NUVB data on Nama Insights →

NUVB FAQ

Is NUVB a buy?: Nama's AI scorecard currently rates Nuvation Bio Sell (3.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NUVB report earnings?: Nuvation Bio's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$0.09.
What is the NUVB price target?: The median analyst price target from 11 analysts is $12.00, with a range of $7.00 – $21.00.
Is NUVB Shariah compliant?: Nama's AAOIFI-style screen reads Nuvation Bio as Not Shariah Compliant. At least one of the three ratios or the industry test failed.